Viridian Therapeutics, Inc./DE Business Exit Costs
Viridian Therapeutics, Inc./DE (VRDN) reported Business Exit Costs of $2.04 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessExitCosts1 · last filed 2017-03-24
- Viridian Therapeutics, Inc./DE business exit costs for fiscal 2016 was $2.04M.
| Period end | Business Exit Costs 12 month |
|---|---|
| 2016-12-31 | $2.04M 10-K · filed 2017-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |